Drugs /

enfortumab vedotin

Back to Drugs List

Overview

Trade Name(s):
Padcev
NCI Definition [1]:
An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of AGS-22CE selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.

Clinical Trials

View Clinical Trials for enfortumab vedotin

Enfortumab vedotin has been investigated in 12 clinical trials, of which 12 are open and 0 are closed. Of the trials investigating enfortumab vedotin, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 4 are phase 3 (4 open).

ER Expression, ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for enfortumab vedotin clinical trials.

Urothelial carcinoma, bladder carcinoma, and adenocarcinoma of the gastroesophageal junction are the most common diseases being investigated in enfortumab vedotin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Enfortumab Vedotin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating enfortumab vedotin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-nectin 4 antibody-drug conjugate asg-22ce, anti-nectin 4 adc asg-22ce, anti-nectin 4 adc asg-22ce, asg-22ce, padcev
Drug Target(s) [2]:
PVRL4
NCIT ID [1]:
C114500

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.